Maintenance Therapy of Narrow-band UV-B Therapy in Patients With Vitiligo
NCT ID: NCT03384342
Last Updated: 2017-12-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
100 participants
INTERVENTIONAL
2017-11-18
2019-05-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of this study was to evaluate the efficacy of Narrow-band UV-B therapy for the prevention of relapse in vitiligo.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
An independent evaluator will obtain the score of vitiligo area (Vitiligo Extent Score) from comparing clinical photographs of before registration and after the clinical trial, and judge whether vitiligo is recurred. This study is a randomized controlled trial, and the investigators plan to compare the recurrence rates of the experimental and control groups using the Chi-squared test.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental group
* For a total period of 12 months, perform Narrow-band UV-B therapy treatment once a month.
* At this time, the dose of Narrow-band UV-B therapy therapy is based on the 50% of the maximum dose that the patient received for the treatment.
Narrow-band UV-B therapy
* Patients treated with NBUVB and showed 75% or more repigmentation rate would be included.
* For a total period of 12 months, narrow-band UV-B therapy is performed once a month.
Control group
* Check for signs of enlarged vitiligo lesions at 3-month intervals for a total period of 12 months.
* If recurrence of vitiligo is observed during the follow-up period, visit the clinic and check for recurrence.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Narrow-band UV-B therapy
* Patients treated with NBUVB and showed 75% or more repigmentation rate would be included.
* For a total period of 12 months, narrow-band UV-B therapy is performed once a month.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients of generalized vitiligo with lesions on the trunk
3. Patients who had treated with Narrow-band UV-B therapy previously and achieved more than 75% lesion improvement
4. Patients who voluntarily agreed to participate in the study
Exclusion Criteria
2. Patients with localized vitiligo and segmental vitiligo
3. Patients who are in a state of physical or mental impairment to perform treatment or pregnant
4. Patients with spreading of vitiligo lesions
5. Patients who do not want to do thie study or who refuse to write a consent form
6. Any other person deemed unsuitable for the examination at the discretion of the examiner
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Catholic University of Korea
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jung Min Bae
Assistant Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St. Vincent's Hospital
Suwon, Gyonggi-do, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jung Min Bae, MD, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VC17DEDI0185
Identifier Type: -
Identifier Source: org_study_id